ERBB2 and congenital rubella syndrome: 1.5-fold to 18.6-fold increase of CRP and interleukin-6 (IL-6) following the administration of CART-HER2 cells infusion were observed in 6/11 and 10/11 patients respectively (Fig. 2A and 2B), however, there was not severe cytokine release symptom (CRS) occurred in this trial.